A Phase 2a trial of ANB020 in patients with severe adult eosinophilic asthma.

Trial Profile

A Phase 2a trial of ANB020 in patients with severe adult eosinophilic asthma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ANB 020 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 According to an AnaptysBio media release, top-line data from this trial are expected in the second quarter of 2018.
    • 10 Oct 2017 Status changed from planning to recruiting according to an AnaptysBio media release.
    • 10 Aug 2017 According to an AnaptysBio media release, the company received clearance from the U.K. Medicines & Healthcare products Regulatory Agency to proceed this phase 2a trial in 24 adult patients with severe eosinophilic asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top